New Diagnostic Tests for Rotavirus and Norovirus Infections Evaluated
|
By LabMedica International staff writers Posted on 21 Oct 2020 |
|
Image: The AFIAS-6 (AFIAS-automated fluorescent immunoassay system) is an automated fluorescent immunoassay system that uses blood, urine, and other samples to measure quantitatively or semi-quantitatively the concentration of targeted analyte (Photo courtesy of Boditech Med Inc).
Acute gastroenteritis is one of the most impactful and common infectious diseases, accounting for millions of deaths annually in young children. Rotavirus and norovirus are leading causes of acute viral gastroenteritis spread through fecal to oral transmission.
For appropriate treatment and infection control, accurate and timely identification of pathogens is necessary. Various diagnostic tools including electron microscopy, latex agglutination, immunochromatographic assay (ICA), enzyme immunoassays, and molecular assays have been developed.
A team of Medical Laboratorians at the Samsung Medical Center (Seoul, Republic of Korea) used a total of 256 clinical stool samples submitted to the clinical microbiology laboratory at a tertiary referral hospital, from November 2018 to January 2019. After routine testing with multiplex real‐time RT‐PCR (rRT‐PCR), residual stool samples were stored at −70 °C prior to analysis.
The team evaluated the performance of Automated Fluorescent Immunoassay System ROTA (AFIAS‐Rota) and NORO (AFIAS‐Noro) assays (Boditech Med Inc, Chuncheon-si, Korea), newly developed automated fluorescent lateral flow immunoassays, in comparison with RIDASCREEN Rotavirus (RIDASCREEN‐Rota) and Norovirus (RIDASCREEN‐Noro) ELISA kits (R‐Biopharm, Darmstadt, Germany) for detection of rotavirus and norovirus. The Boditech assays were read after 12 minutes using that company’s AFIAS‐6 scanner and for the R-Biopharm assays the fluorescence was analyzed using a GEMINI spectrofluorometer (STRATEC Biomedical AG, Birkenfeld, Germany).
The investigators reported AFIAS‐Rota and RIDASCREEN Rotavirus had almost perfect agreement and substantial agreement was observed between AFIAS‐Noro and RIDASCREEN Norovirus. For detection of rotavirus, AFIAS and RIDASCREEN assays showed satisfactory diagnostic sensitivity (100% and 97.8%, respectively) and specificity (99.5% and 99.1%). For detection of norovirus, the RIDASCREEN assay showed significantly higher sensitivity than the AFIAS‐Noro (86.0% and 66.0%, respectively). Analytic specificity of AFIAS‐Rota/Noro assays showed no cross‐reactivity against any other bacteria (14 strains) or viruses (two strains). Hands‐on time (six minutes) and turnaround time (26 minutes) required to perform AFIAS assays were much shorter than those required for RIDASCREEN assays (20 and 150 minutes, respectively).
The authors concluded that the AFIAS‐Rota/Noro assays showed overall excellent agreement with the RIDASCREEN assays. Although the AFIAS‐Noro assay exhibited lower sensitivity than the RIDASCREEN Norovirus assay for detection of norovirus, the AFIAS‐Rota/Noro assays could be useful as a rapid initial screening test in clinical laboratories due to its convenience and rapid turnaround time. The study was published on September 23, 2020 in the Journal of Clinical Laboratory Analysis.
Related Links:
Samsung Medical Center
Boditech Med Inc
R‐Biopharm
STRATEC Biomedical AG
For appropriate treatment and infection control, accurate and timely identification of pathogens is necessary. Various diagnostic tools including electron microscopy, latex agglutination, immunochromatographic assay (ICA), enzyme immunoassays, and molecular assays have been developed.
A team of Medical Laboratorians at the Samsung Medical Center (Seoul, Republic of Korea) used a total of 256 clinical stool samples submitted to the clinical microbiology laboratory at a tertiary referral hospital, from November 2018 to January 2019. After routine testing with multiplex real‐time RT‐PCR (rRT‐PCR), residual stool samples were stored at −70 °C prior to analysis.
The team evaluated the performance of Automated Fluorescent Immunoassay System ROTA (AFIAS‐Rota) and NORO (AFIAS‐Noro) assays (Boditech Med Inc, Chuncheon-si, Korea), newly developed automated fluorescent lateral flow immunoassays, in comparison with RIDASCREEN Rotavirus (RIDASCREEN‐Rota) and Norovirus (RIDASCREEN‐Noro) ELISA kits (R‐Biopharm, Darmstadt, Germany) for detection of rotavirus and norovirus. The Boditech assays were read after 12 minutes using that company’s AFIAS‐6 scanner and for the R-Biopharm assays the fluorescence was analyzed using a GEMINI spectrofluorometer (STRATEC Biomedical AG, Birkenfeld, Germany).
The investigators reported AFIAS‐Rota and RIDASCREEN Rotavirus had almost perfect agreement and substantial agreement was observed between AFIAS‐Noro and RIDASCREEN Norovirus. For detection of rotavirus, AFIAS and RIDASCREEN assays showed satisfactory diagnostic sensitivity (100% and 97.8%, respectively) and specificity (99.5% and 99.1%). For detection of norovirus, the RIDASCREEN assay showed significantly higher sensitivity than the AFIAS‐Noro (86.0% and 66.0%, respectively). Analytic specificity of AFIAS‐Rota/Noro assays showed no cross‐reactivity against any other bacteria (14 strains) or viruses (two strains). Hands‐on time (six minutes) and turnaround time (26 minutes) required to perform AFIAS assays were much shorter than those required for RIDASCREEN assays (20 and 150 minutes, respectively).
The authors concluded that the AFIAS‐Rota/Noro assays showed overall excellent agreement with the RIDASCREEN assays. Although the AFIAS‐Noro assay exhibited lower sensitivity than the RIDASCREEN Norovirus assay for detection of norovirus, the AFIAS‐Rota/Noro assays could be useful as a rapid initial screening test in clinical laboratories due to its convenience and rapid turnaround time. The study was published on September 23, 2020 in the Journal of Clinical Laboratory Analysis.
Related Links:
Samsung Medical Center
Boditech Med Inc
R‐Biopharm
STRATEC Biomedical AG
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Pneumonia Test
Pneumocystis ELITe MGB® Kit
New
Automated IFA Analyzer
HELIOS HTC
Latest Immunology News
- Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
- Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
- Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
- Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
- New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
Channels
Clinical Chemistry
view channel
CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
Parkinson’s disease and dementia with Lewy bodies are frequently misdiagnosed, often being confused with Alzheimer’s disease because of overlapping symptoms. Objective diagnostics for these synucleinopathies... Read more
Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
Breast cancer is the most commonly diagnosed cancer among women globally and remains a leading cause of cancer-related deaths in more than 100 countries. Current diagnostic pathways rely on mammography,... Read more
Molecular Diagnostics
view channel
Simple Nasal Swab May Reveal Early Signs of Alzheimer’s Disease
Alzheimer’s disease affects millions worldwide but remains difficult to detect at its earliest, pre-symptomatic stage. Clinicians need tools that can identify biological changes before cognitive symptoms... Read more
Blood Biomarker Predicts Cognitive Outcomes After Cardiac Arrest
Long-term cognitive impairment is a frequent consequence of out-of-hospital cardiac arrest yet early prediction remains difficult. Clinicians commonly use blood-based markers to estimate brain injury risk... Read more
Hematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Immunology
view channel
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read more
Pathology
view channel
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read more
New Chromogenic Culture Media Enable Rapid Detection of Candida Infections
Invasive Candida infections are challenging for healthcare systems, with some strains spreading rapidly in hospitals and showing resistance to multiple antifungal drugs. Candida auris is associated with... Read more
Technology
view channel
Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
Pneumonia is commonly confirmed with chest X-rays or laboratory assays that can take hours, delaying clinical decisions in acute and outpatient settings. Breath-based diagnostics promise faster answers... Read more
New Electronic Pipette Enhances Workflows with Touchscreen Control
Manual pipetting remains a routine yet error-prone step that can affect reproducibility and throughput in clinical and research laboratories. Training demands and ergonomic strain also add variability... Read more
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Integrated DNA Technologies Expands into Clinical Diagnostics
Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx, marking the company’s first in vitro diagnostic(IVD) offerings and its... Read more
